BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24118322)

  • 41. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
    Garbino J; Markham L; Matulionyte R; Rives V; Lew D
    Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fusariosis in burn patients: A systematic review of case reports.
    Piccoli P; Lucini F; Al-Hatmi AMS; Rossato L
    Med Mycol; 2024 Mar; 62(3):. PubMed ID: 38379099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?
    Nucci M; Shoham S; Abdala E; Hamerschlak N; Rico JC; Forghieri F; Nouér SA; Cappellano P; Solza C; Gonzaga Y; Nadali G; Nucci F; Colombo AL; Albuquerque AM; Queiroz-Telles Filho F; Lima CBL; Arrais-Rodrigues C; Rocha V; Marty FM
    Mycoses; 2019 May; 62(5):413-417. PubMed ID: 30720902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of invasive mycoses in hematology patients: current approaches.
    Perfect JR
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):5-14. PubMed ID: 15651177
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disseminated fusariosis with cerebral involvement in a patient with acute myeloid leukemia: Successful outcome with intrathecal -and systemic antifungal treatment.
    Risum M; Overgaard UM; Rubek N; Haastrup EK; Hare RK; Helweg-Larsen J
    J Infect Chemother; 2022 Sep; 28(9):1324-1328. PubMed ID: 35641412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of correlation of ECV and outcome in an in vivo murine model of systemic fusariosis.
    Navarro-Rodríguez P; Guevara-Suarez M; Paredes K; Celis A; Guarro J; Capilla J
    Diagn Microbiol Infect Dis; 2018 Oct; 92(2):124-126. PubMed ID: 30201117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity.
    Falci DR; Lunardi LW; Ramos CG; Bay MB; Aquino VR; Goldani LZ
    Clin Infect Dis; 2010 Mar; 50(5):e26-9. PubMed ID: 20121575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
    Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
    Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Invasive Fusariosis: A Single Pediatric Center 15-Year Experience.
    Schwartz KL; Sheffield H; Richardson SE; Sung L; Morris SK
    J Pediatric Infect Dis Soc; 2015 Jun; 4(2):163-70. PubMed ID: 26407418
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
    Quinteros A R; Fica C A; Abusada A N; Muñoz C L; Novoa M C; Gallardo A C
    Rev Chilena Infectol; 2010 Feb; 27(1):25-33. PubMed ID: 20140311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis.
    Fernández-Cruz A; Semiglia MA; Guinea J; Martínez-Jiménez MDC; Escribano P; Kwon M; Rodríguez-Macías G; Chamorro-de-Vega E; Rodríguez-González C; Navarro R; Galar A; Sánchez-Carrillo C; Díez-Martín JL; Muñoz P
    Med Mycol; 2020 Apr; 58(3):300-309. PubMed ID: 31231772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies.
    Abidi MZ; Sohail MR; Cummins N; Wilhelm M; Wengenack N; Brumble L; Shah H; Jane Hata D; McCullough A; Wendel A; Vikram HR; Kusne S; Litzow M; Letendre L; Lahr BD; Poeschla E; Walker RC
    Mycoses; 2014 Nov; 57(11):687-98. PubMed ID: 25040241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
    Drew R
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():36-44. PubMed ID: 16713192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined therapy in treatment of murine infection by Fusarium solani.
    Ruíz-Cendoya M; Mariné M; Guarro J
    J Antimicrob Chemother; 2008 Sep; 62(3):543-6. PubMed ID: 18495651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Guideline based treatment of invasive aspergillosis].
    Karthaus M
    Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
    Perfect JR
    Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?
    Schneemann M; Bachli EB
    Clin Infect Dis; 2004 Jan; 38(2):303-4; author reply 306-7. PubMed ID: 14699468
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
    Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
    Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
    Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
    Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are there risk factors for acute renal failure in adult patients using deoxycholate amphotericin B?
    Tuon FF; Koenig F; Jacometto D; Rocha JL
    Rev Iberoam Micol; 2013 Jan; 30(1):21-4. PubMed ID: 22995903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.